NCT05351840View on ClinicalTrials.gov

To Evaluate the Pharmacokinetic Interactions and Safety in Healthy Volunteers

PHASE1CompletedINTERVENTIONAL

Enrollment

31

Participants

Timeline

Start Date

November 2, 2020

Primary Completion Date

December 19, 2020

Study Completion Date

January 15, 2021

Conditions

Healthy

Interventions

DRUG

LivaloV

Treatment A, Tablet, Oral, QD for 7 Days

DRUG

A

Treatment B, Tablet, Oral, QD for 10 Days

DRUG

LivaloVA

Treatment C, Tablet, Oral, QD for 7 Days

Trial Locations (1)

Unknown

Clinical Trial Center, Chungnam National University Hospital, Daejeon

Sponsors

Lead Sponsor

JW Pharmaceutical

All Listed Sponsors

lead

JW Pharmaceutical

INDUSTRY